Real-world disproportionality analysis of cardiac failure associated with novel antineoplastic agents in breast cancer: a pharmacovigilance study
This study underscores drug-specific differences in CF risk among breast cancer therapies and highlights the importance of individualized cardiovascular risk assessment during treatment planning and monitoring.
Authors
- FangJie Liu (ORCID: https://orcid.org/0000-0002-3771-5566)
- Lanqing Huo (ORCID: https://orcid.org/0000-0002-4578-625X)
- Changyuan Guo (ORCID: https://orcid.org/0000-0002-0568-9527)
- Yingjia Wu
- Hui Li (ORCID: https://orcid.org/0000-0002-5740-2655)
- Qin Guo
Institutions
- Sun Yat-sen University (CN)
- Sun Yat-sen University Cancer Center (CN)
- Shenzhen Second People's Hospital (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-09-29
- DOI
- https://doi.org/10.3389/fimmu.2025.1680909
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 1.05